Ibogaine Side Effects: What Happens During and After Ceremony

Ibogaine has significant, predictable side effects: QT prolongation, nausea, ataxia, and 12–24 hours of intense waking experience. The cardiovascular effect is the one that determines who can and cannot safely proceed. Everything else is expected, monitored, and manageable with proper preparation and on-site medical oversight.

The word “side effects” covers two distinct categories. Some are what the medicine does in anyone who takes it—expected, documented, temporary. Others are contraindications: conditions that make the medicine dangerous regardless of preparation or intent. Understanding the difference between them is not academic. It is what distinguishes a completed screening process from a ceremony that should not have happened.

Expected Effects vs. Contraindications

Ibogaine is not a standard psychedelic in mechanism or in what it demands from the person taking it. It binds multiple receptor types—opioid receptors, glutamate receptors, sigma receptors—producing an experience qualitatively different from psilocybin, MDMA, or ayahuasca. The duration alone distinguishes it: 12–24 hours of active experience followed by 2–3 days of recovery is not a recreational time commitment.

The expected effects of ibogaine—the ones a medically appropriate candidate should anticipate—are demanding but not dangerous for someone who has been properly screened. The contraindications are a different matter. Cardiac arrhythmia, severe liver disease, active psychosis, current SSRIs: these are not risk factors to weigh against benefit. They are reasons not to proceed.

The purpose of medical screening before ibogaine ceremony is not to satisfy a legal requirement or to manage liability. It is to establish which category a given person is in.

Physical Effects During Ceremony

The physical experience during ceremony is demanding. It is not dangerous for a medically appropriate candidate, but it is not comfortable. Anyone who enters expecting a pleasant altered state has the wrong frame.

The most consistent physical effects during the active window:

• Ataxia—profound loss of motor coordination. Standing and walking independently are not possible for most of the active window. Participants remain lying down. This resolves as the medicine clears.
• Nausea and vomiting—common, particularly in the first few hours. Not universal, but frequent enough to expect rather than be surprised by.
• Sound sensitivity (hyperacusis)—ibogaine amplifies auditory input significantly. The acoustic environment of the ceremony matters.
• Light sensitivity (photosensitivity)—eyes are typically kept closed or covered throughout the active window.
• Body temperature fluctuations—perceived temperature can shift; blankets and control of ambient temperature are part of the physical setup.
• Suppression of sleep—ibogaine prevents normal sleep during the active window, then produces profound fatigue afterward.

The 12–24 hour active window is not uniformly intense throughout. The most demanding physical effects concentrate in the first several hours. The later phase shifts toward a more inward, less intensely physical experience—the period in which most of the psychological work happens.

Cardiovascular Effects: The Risk That Requires Monitoring

Ibogaine blocks the hERG potassium channel in cardiac tissue. This prolongs the QT interval—the period on an electrocardiogram reflecting the time it takes for the heart's ventricles to repolarise between beats. QT prolongation is not dangerous for everyone. In people with a healthy baseline EKG and no structural heart disease, it is manageable with on-site cardiac monitoring during the active window. In people with pre-existing QT prolongation, structural heart disease, or who are taking other QT-prolonging substances, it creates meaningful risk of a potentially fatal arrhythmia.

Any ibogaine provider that skips cardiac screening is not operating safely. A pre-ceremony EKG is not a formality or a hedge against liability—it is the mechanism by which cardiac contraindications are identified before ceremony rather than during it. Providers who skip this step are cutting costs at the expense of the person in the chair.

The on-site physician during ceremony exists because of this risk. Continuous cardiac monitoring throughout the active window allows for immediate response if parameters change.

The 2023 Stanford study published in Nature Medicine treated 30 special operations veterans with ibogaine HCl under full medical supervision, including continuous cardiac monitoring, and found average symptom reductions of 88% for PTSD, 87% for depression, and 81% for anxiety at one month. The rigour of the screening and monitoring protocol was not incidental to those results. It was the structure that made those results possible.

More detail on the mechanism and the screening it requires is at the ibogaine cardiac safety overview.

The Psychological Experience

Ibogaine does not reliably produce euphoria. It does not produce a reliable sense of connection, wonder, or expansion. What it reliably produces is a detailed confrontation with the person's own history—a biographical review of what has been avoided, suppressed, or unresolved.

This confrontational character is precisely what makes ibogaine therapeutically relevant for people with treatment-resistant conditions. It is also what makes expectations about the experience critically important in preparation. The medicine does not deliver what people want. It tends to deliver what they need—and those are often not the same thing.

People who enter ceremony seeking an experience—something to talk about, a shortcut to insight, a way of feeling something without the sustained work of change—tend to find it disorienting rather than illuminating. Ibogaine does not serve those expectations. What the person leaves with is whatever they were able to honestly encounter, not what they arrived hoping for.

The visual content of the experience varies. Some people encounter what can only be described as biographical sequences—specific memories, relationships, patterns, presented in ways that allow examination that was not previously possible. Others experience more abstract or geometric material alongside the psychological content. Auditory phenomena are also common throughout the active window.

Psychological distress during ceremony is possible, particularly for people who encounter material they were not prepared to face. This is a reason for thorough preparation and professional facilitation—not a reason to avoid the medicine for appropriate candidates, but a reason why unsupported ceremony is not a reasonable option.

After Ceremony: The First 72 Hours

The 2–3 days following an ibogaine ceremony are not a return to baseline. The acute effects resolve, but what follows is a period of heightened sensitivity, profound fatigue, and what experienced facilitators describe as a kind of permeability that requires protection rather than stimulation.

Common experiences in the first 72 hours:

• Profound physical fatigue—sleep returns after the active window, often deeply
• Heightened emotional sensitivity—material and situations that would not normally land strongly may feel significant
• Continued cognitive processing—what was encountered during ceremony continues to surface and integrate
• Reduced appetite in the first 24–48 hours
• Disorientation about what was experienced and what it means is not unusual

Returning immediately to stressful environments, obligations, or screens after ceremony tends to interrupt the processing that the recovery period is designed to support. The recovery window is built into programme timing for a reason. Planning the transition from ceremony to ordinary life carefully is part of preparation, not an afterthought.

Longer-Term Effects: What Noribogaine Does

Noribogaine is ibogaine's primary active metabolite, produced in the liver within hours of ingestion. It has a substantially longer half-life than ibogaine itself and remains pharmacologically active for weeks to months after a flood-dose ceremony. It is noribogaine, more than ibogaine, that produces the sustained effects that follow ceremony.

Noribogaine's pharmacological activity includes serotonin transporter (SERT) inhibition, continued opioid receptor activity that contributes to craving suppression, and what appears to be stimulation of GDNF—glial cell line-derived neurotrophic factor, a growth factor associated with neuroplasticity and the capacity to form new patterns of response.

The practical implications for the period after ceremony:

• SSRIs and SNRIs should not be resumed immediately after ceremony—concurrent activity with noribogaine's SERT inhibition creates serotonin syndrome risk. Medical guidance on timing is part of the post-ceremony protocol.
• The neuroplasticity window created by noribogaine is real, documented, and finite. What happens in the weeks and months after ceremony largely determines whether the ceremony produces durable change.
• Mood changes in the weeks following ceremony are common. Some participants experience a period of reduced craving and elevated mood followed by gradual normalisation as noribogaine clears. The integration work done during this window is what determines whether that period produces lasting change.

Who Is Not Right for This

The medical contraindications for ibogaine ceremony are not risk factors to weigh. They are reasons not to proceed.

Absolute medical contraindications:

• QT prolongation or significant cardiac arrhythmia on baseline EKG—the most critical safety filter, identified through pre-ceremony screening
• Recent myocardial infarction or structural heart disease
• Severe liver disease—ibogaine is metabolised in the liver; impaired function alters the pharmacokinetic profile in ways that increase risk
• Severe kidney disease
• Active psychosis or schizophrenia-spectrum disorder—ibogaine amplifies what is present; it does not create stability out of instability
• Current SSRIs or SNRIs—an absolute contraindication. Physician-supervised taper to completion is required before any discussion of ceremony dates. This is not a preference.
• Methadone—a specific multi-month transition protocol is required, not simply stopping
• Lithium and certain other psychiatric medications—specific drug interactions exist; full medication review is part of intake
• Pregnancy

Situational contraindications:

• Acute psychiatric crisis—someone in a state of acute instability is not an appropriate candidate regardless of motivation or urgency to proceed
• No integration plan in place—ceremony without a plan for the weeks following is not a complete programme
• Primary motivation is an experience rather than a process—ibogaine is not a recreational psychedelic; someone seeking a profound experience rather than the work of confronting what the medicine surfaces is likely to find it disorienting

The conversation that ends in a no is one of the most important functions of any legitimate intake process. People in serious need who have found a potential path do not receive that answer easily. Communicating it directly—without softening what the medical or situational reality actually is—is an act of care, not rejection.

Is This Right for You?

The side effects of ibogaine are significant and predictable. They are also manageable for medically appropriate candidates—candidates identified through thorough screening, not through personal judgement about their own health. What determines whether someone is an appropriate candidate is not motivation, not urgency, and not how much they want it. It is what a 12-lead EKG and a complete medical history review show.

If you are researching ibogaine because conventional approaches have not been adequate, the FAQ covers the most common questions about screening, what to expect from intake, and whether this is an appropriate path. The ceremony page covers what the programme includes. Ongoing clinical trials are tracking ibogaine's safety and efficacy in controlled settings; the results building on the 2023 Stanford study will add to the evidence base over the coming years.

If you are not a candidate—a confirmed cardiac contraindication, a current medication that cannot be safely tapered in the near term, a clinical state that requires stabilisation first—that will be communicated directly in the intake process. It is not the outcome anyone wants. It is the most accurate and useful thing the process can do.

Applications are open. Every application receives a personal response within 2–3 business days.